Safety and Pharmacokinetics of RTH258 in Subjects With Age-Related Macular Degeneration

Overview

The purpose of this study is to assess the systemic pharmacokinetics (PK) and safety of 2 different doses of brolucizumab (3 milligrams (mg)/50 microliters (μL) and 6 mg/50 μL) when administered at 4-week intervals for a total of 3 intravitreal injections in subjects with neovascular age-related macular degeneration (AMD).

Full Title of Study: “A Randomized, Double Masked, Three Dose Safety and Pharmacokinetic Study of RTH258 Following Intravitreal (IVT) Injection in Subjects With Neovascular Age-Related Macular Degeneration”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Other
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: September 6, 2016

Detailed Description

This study has 2 arms with a 1:1 randomization. Randomization will be stratified by Japanese ethnicity. Half of the subjects in each arm will be of Japanese ethnicity. The other half of the subjects in each arm will be non-Japanese. Subjects in both arms will have visits at Screening, Day 0 (Baseline), Day 1 (24 hours post first injection), Day 3, Day 14, Day 21, Day 28, Day 56, Day 57 (24 hours post the injection on Day 56) and Day 84.

Interventions

  • Drug: Brolucizumab 3 mg/50 μL
    • Administered as an intravitreal injection
  • Drug: Brolucizumab 6 mg/50 μL
    • Administered as an intravitreal injection

Arms, Groups and Cohorts

  • Experimental: Brolucizumab 3 mg
    • Brolucizumab 3 mg/50 μL administered as an intravitreal injection 3 times at 4-week intervals with follow-up for 84 days from the initial injection
  • Experimental: Brolucizumab 6 mg
    • Brolucizumab 6 mg/50 μL administered as an intravitreal injection 3 times at 4-week intervals with follow-up for 84 days from the initial injection

Clinical Trial Outcome Measures

Primary Measures

  • Maximum Analyte Serum Concentration [Cmax (ng/mL)]
    • Time Frame: Day 0 (predose), 6 hr, 24 hr, 72 hr, 168 hr, 336 hr, 504 hr, 672 hr
    • Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method. These data were analyzed using a noncompartmental pharmacokinetic (PK) method.
  • Time to Reach Maximum Analyte Serum Concentration [Tmax (h)]
    • Time Frame: Day 0 (predose), 6 hr, 24 hr, 72 hr, 168 hr, 336 hr, 504 hr, 672 hr
    • Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method. These data were analyzed using a noncompartmental pharmacokinetic (PK) method.
  • Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration [AUC0-tlast (ng*h/mL)]
    • Time Frame: Day 0 (predose), 6 hr, 24 hr, 72 hr, 168 hr, 336 hr, 504 hr, 672 hr
    • Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method. These data were analyzed using a noncompartmental pharmacokinetic (PK) method.
  • Area Under the Concentration-time Curve From 0 to Infinity [AUC0-inf (ng*h/mL)]
    • Time Frame: Day 0 (predose), 6 hr, 24 hr, 72 hr, 168 hr, 336 hr, 504 hr, 672 hr
    • Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method. These data were analyzed using a noncompartmental pharmacokinetic (PK) method.
  • Elimination Half-life in Serum [t1/2 (h)]
    • Time Frame: Day 0 (predose), 6 hr, 24 hr, 72 hr, 168 hr, 336 hr, 504 hr, 672 hr
    • Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method. These data were analyzed using a noncompartmental pharmacokinetic (PK) method.
  • Concentration of RTH258 Obtained 24 Hours Post Day 0 Injection [C24hr (ng/mL)]
    • Time Frame: Day 1
    • Serum concentration at the specified collection time point was quantitated, where possible, using a validated immunoassay method. The data were analyzed using a noncompartmental pharmacokinetic (PK) method.
  • Concentration of RTH258 Obtained 24 Hours Post Day 56 Injection [C24hr (ng/mL)]
    • Time Frame: Day 57
    • Serum concentration at the specified collection time point was quantitated, where possible, using a validated immunoassay method. The data were analyzed using a noncompartmental pharmacokinetic (PK) method.

Secondary Measures

  • Percentage of Subjects With Positive Anti-drug Antibody (ADA) Status (Test)
    • Time Frame: Day 0 (predose), Day 28, Day 84
    • A positive ADA status is defined as induced ADA status with ADA negative at predose and with a post-dose titer value increase of 2 or more dilutions at any time point or boosted ADA status with ADA positive at predose and a post-dose titer value increase by more than 3-fold (1 dilution) at any time point.

Participating in This Clinical Trial

Inclusion Criteria

  • Provide written informed consent;
  • Active choroidal neovascularization (CNV) lesions secondary to AMD that affect the central subfield in the study eye;
  • Best Corrected Visual Acuity (BCVA) > 23 letters in the study eye at Baseline;
  • 50 years of age or older at the time of Screening.

Exclusion Criteria

  • Any active ocular infection or inflammation;
  • Treatment with aflibercept (EYLEA®), bevacizumab (AVASTIN®), ranibizumab (LUCENTIS®), brolucizumab, or an investigational drug for neovascular AMD prior to enrollment in the study, as specified in protocol;
  • Ocular surgery in the study eye, as specified in protocol;
  • Uncontrolled glaucoma in the study eye, as specified in protocol;
  • Use of steroids in the study eye, as specified in protocol;
  • Medical conditions that may prevent study completion;
  • Pregnant or nursing (lactating) women;
  • Women of child-bearing potential unless using contraception;
  • Uncontrolled blood pressure, as specified in protocol;
  • Other protocol-specified exclusion criteria may apply.

Gender Eligibility: All

Minimum Age: 50 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Alcon Research
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Alcon, A Novartis Division, Study Director, Alcon, A Novartis Division

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.